FundedIQ
Biotechnology

TriSalus Life Sciences: Funding, Investors & Team (Sep 2026)

The goal of TriSalus Life Sciences, an immunotherapy business, is to prolong and enhance the lives of people with liver and pancreatic malignancies. The most significant barriers that limit the effectiveness of therapeutics for liver and pancreatic tumors are immune response suppression and ineffective drug delivery caused by high intratumoral pressure, and TriSalus' organ-specific platform integrates novel therapeutics and innovative drug delivery technology to address these issues.

trisaluslifesci.com LinkedIn Westminster, United States 51-100 employees
Biotechnology Developer Platform Hardware Medical B2B
Total raised
$23.5M
Rounds
1
Latest
Series E
Nov 2022

TriSalus Life Sciences has raised $23.5M across 1 funding round on record, the most recent a Series E of $23.5M announced in Nov 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

TriSalus Life Sciences Company Profile and Key Stats

Total funding raised
$23.5M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series E
$23.5M in Nov 2022
Employees
51-100
reported band
Headquarters
Westminster, United States

Latest funding round on record: Nov 2022.

TriSalus Life Sciences Funding Rounds

Date
Round
Amount
Series E
$23.5M

TriSalus Life Sciences Founders and Leadership Team

Name
Role
Contact
Mary Szela
CEO

No contact details are on record for this team yet.

TriSalus Life Sciences Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,183
$8.0M
29,981
$7.5M
270
$100M

TriSalus Life Sciences' latest round of $23.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like TriSalus Life Sciences in Biotechnology and Westminster

Companies Similar to TriSalus Life Sciences

Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…

Series E $92.5M

Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…

Series B $40.0M

Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…

Private Equity

Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…

Undisclosed round $12.0M

SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…

Undisclosed round $960k

DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…

Series B $4.0M

Solstice Oncology is a clinical stage immuno-oncology company

Series A $225M

Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…

Series F $275M

BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…

Series A $116M

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

TriSalus Life Sciences Funding FAQs

What does TriSalus Life Sciences do?

The goal of TriSalus Life Sciences, an immunotherapy business, is to prolong and enhance the lives of people with liver and pancreatic malignancies. The most significant barriers that limit the effectiveness of therapeutics for liver and pancreatic tumors are immune response suppression and ineffective drug delivery caused by high intratumoral pressure, and TriSalus' organ-specific platform integrates novel therapeutics and innovative drug delivery technology to address these issues.

How much funding has TriSalus Life Sciences raised?

TriSalus Life Sciences has raised $23.5M across 1 round on record. The most recent is a Series E of $23.5M announced in Nov 2022.

When did TriSalus Life Sciences last raise funding?

TriSalus Life Sciences' most recent funding round on record is a Series E of $23.5M, announced in Nov 2022.

Who is the CEO of TriSalus Life Sciences?

Mary Szela is listed as CEO at TriSalus Life Sciences.

Where is TriSalus Life Sciences headquartered?

TriSalus Life Sciences is based in Westminster, Colorado, United States.

How many employees does TriSalus Life Sciences have?

TriSalus Life Sciences is in the 51-100 employee band.

How does TriSalus Life Sciences' funding compare to other Biotechnology startups?

TriSalus Life Sciences' latest round of $23.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.

About FundedIQ's TriSalus Life Sciences Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TriSalus Life Sciences is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.